Loading clinical trials...

Transcranial Direct Current Stimulation to Reduce Chronic Pain in Patients With Chronic Inflammatory Bowel Diseases | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Transcranial Direct Current Stimulation to Reduce Chronic Pain in Patients With Chronic Inflammatory Bowel Diseases

NCT02048137•Charite University, Berlin, Germany

View on ClinicalTrials.gov

Summary

In the study we test whether transcranial direct current stimulation can reduce the perception of pain in patients with chronic inflammatory bowel diseases. Hypothesis: Transcranial direct current stimulation can reduce the perception of pain in patients with chronic inflammatory bowel diseases.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Inflammatory bowel disease
•Chronic pain (more than 3 months)
•Pain (VAS \> 3/10)

Exclusion Criteria

•Contraindication to transcranial direct current stimulation
•Pregnancy
•Sever internal or psychiatric condition

Locations (1)

Charite University Medicine

Berlin, Germany

Key Dates

Start Date

January 1, 2014

Primary Completion Date

December 1, 2016

Last Updated

January 24, 2018

Enrollment

ESTIMATED participants

Conditions

Inflammatory Bowel Disease

Interventions

Transcranial direct current stimulation

DEVICE

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883

Inflammatory Bowel DiseasesCrohn's Disease

View study

RECRUITINGNA

Impact of Morning Light Therapy in IBD

NCT07207200

Inflammatory Bowel Disease

View study

RECRUITING

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 24, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Transcranial Direct Current Stimulation to Reduce Chronic Pain in Patients With Chronic Inflammatory Bowel Diseases

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Impact of Morning Light Therapy in IBD

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD

A Phase I Study of HW201877 in Healthy Subjects